European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 27-31 , January 2008

Effectiveness of eprosartan in diabetic hypertensive patients

  • N.R. Robles

      Affiliations

    • Department of Nephrology, Hospital Infanta Cristina, Badajoz, Spain
    • Corresponding Author InformationCorresponding author: Service of Nephrology Hospital Infanta Cristina Carretera de Portugal s/n E-06080 Badajoz, Spain. Tel.: +34 942 218100; fax: +34 924 218117.
    • ,
  • B. Martín-Águeda

      Affiliations

    • Medical Department Juste S.A.Q.F., Madrid, Spain
    • ,
  • F. López-Muñoz

      Affiliations

    • Department of Pharmacology, University of Alcalá, Madrid, Spain
    • ,
  • C. Álamo

      Affiliations

    • Department of Pharmacology, University of Alcalá, Madrid, Spain
    • ,
  • on behalf of the investigators of the ESTEPP study

Received 1 November 2006 ,Revised 31 March 2007 ,Accepted 20 April 2007.

References 

  1. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens. 1998;16:761–769
  2. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35:1038–1042
  3. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension. 2003;41:431–436
  4. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461–1464
  5. Guidelines Committee of the 2003 . European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053
  6. Ruilope L, Jäger B. Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003;4:107–114
  7. Innes GT. Angiotensin II antagonists in systolic blood pressure control. Hosp Med. 2001;62:773–777
  8. Robles NR, Martín Águeda B, Lopez Muñoz F, Alamo C, ESTEPP Study Group Investigators . Effectiveness and safety of eprosartan treatment on pulse pressure in hypertensive patients. Int J Clin Pract. 2005;59:478–484
  9. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  10. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–684
  11. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97–104
  12. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349–1354
  13. SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264
  14. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–1285
  15. Staessen JA, Fagard R, Thijs L, et al. Randomised, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764
  16. Reid CM, Ryan P, Wing LMH. The 2nd Australian National Blood Pressure Study (ANBP2). In:  Black HR editors. Clinical Trials in Hypertension. New York, NY: Marcel Dekker; 2001;p. 587–604
  17. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–872
  18. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press. 1999;8:114–121
  19. De la Sierra A, Muñoz A, Arcos E, Relats J, ESTEPA Study investigators . Efecto del tratamiento con eprosartan sobre la presión de pulso. Factores predictores de respuesta. Hipertensión. 2003;20:56–62
  20. Safar M, Van Bortel L, Struijker Boudier H. Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res. 1997;81:34–67
  21. Asmar R, Benetos A, Chaouche-Teyara K, Raveau-Landon C, Safar M. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol. 1993;72:794–798
  22. Benetos A, Lafleche A, Asmar R, Gautier S, Safar A, Safar ME. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens. 1996;10:77–82
  23. Gradman AH, Gray J, Maggiacomo F, et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Clin Ther. 1999;17:129–136
  24. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15:15–24
  25. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens. 1999;17:129–136

PII: S0953-6205(07)00246-4

doi: 10.1016/j.ejim.2007.04.022

European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 27-31 , January 2008

Article Tools

* Image Usage & Resolution